Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GS-5745

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug GS-5745?

GS-5745 is an investigational drug.

There have been 11 clinical trials for GS-5745. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Esophageal Neoplasms, Adenocarcinoma, and Colitis, Ulcerative. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].

There are three US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for GS-5745
GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisGilead SciencesPhase 2
Effect of GS-5745 on FEV1 in Adults With Cystic FibrosisGilead SciencesPhase 2
GS-5745 as Monotherapy and in Combination With Chemotherapy in Japanese Participants With Gastric or Gastroesophageal Junction AdenocarcinomaGilead SciencesPhase 1

See all GS-5745 clinical trials

Clinical Trial Summary for GS-5745

Top disease conditions for GS-5745
Top clinical trial sponsors for GS-5745

See all GS-5745 clinical trials

US Patents for GS-5745

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-5745   Start Trial Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
GS-5745   Start Trial Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
GS-5745   Start Trial Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation (Wilmington, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.